Trial Profile
Compliance, persistence healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2011
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; ACE inhibitors; Angiotensin receptor antagonists
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 07 Apr 2011 New trial record